Therapeutic targeting of receptor tyrosine kinases in lung cancer

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 3, 2005, Pages 533-559

  Choong, Nicholas W ^a   Ma, Patrick C ^a   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Lung cancer; Receptor tyrosine kinase

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; AXITINIB; BEVACIZUMAB; BISPECIFIC ANTIBODY; CALIXARENE; CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GELDANAMYCIN; GEMCITABINE; GFA 116; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR ANTAGONIST 116; IMATINIB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INDOLE DERIVATIVE; IRINOTECAN; LAPATINIB; MATUZUMAB; MDX 447; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY ICR62; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEGINTERFERON; PELITINIB; PHA 665752; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE; QUINAZOLINE DERIVATIVE; RECEPTOR ANTIBODY; SEMAXANIB; SU 11274; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN DECOY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; YTTRIUM 90;

ANAPHYLAXIS; ANOREXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME MECHANISM; FOLLICULITIS; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG CANCER; LUNG CARCINOGENESIS; MAXIMUM TOLERATED DOSE; NAUSEA; NONHUMAN; OUTCOMES RESEARCH; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 21244500970     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.3.533     Document Type: Review

References (312)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55:10-30.
2. SHIBUYA K, MATHERS CD, BOSCHI-PINTO C, LOPEZ AD, MURRAY CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer (2002) 2:37.
3. SPIRA A, ETTINGER DS: Multidisciplinary management of lung cancer. N. Engl. J. Med. (2004) 350:379-392.
4. ARRIAGADA R, BERGMAN B, DUNANT A, LE CHEVALIER T, PIGNON JP, VANSTEENKISTE J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. (2004) 350:351-360.
5. ROSELL R, GOMEZ-CODINA J, CAMPS C et al.: Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer (1999) 26:7-14.
6. ROTH JA, ATKINSON EN, FOSSELLA F et al.: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer (1998) 21:1-6.
7. SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (2002) 346:92-98.
8. SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously created with platinum-based chemotherapy. J. Clin. Oncol. (2000) 18:2095-2103.
9. FERRARA N: VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer (2002) 2:795-803.
10. SHEPHERD FA, PEREIRA J, CIULEANU TE et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J. Clin. Oncol. (2004) 22:Abstract 7022.
11. KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290:2149-2158.
12. NODA K, NISHIWAKI Y, KAWAHARA M et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. (2002) 346:85-91.
13. TAKADA M, FUKUOKA M, KAWAHARA M et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan. Clin. Oncol. Group Study 9104. J. Clin. Oncol. (2002) 20:3054-3060.
14. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
15. GSCHWIND A, FISCHER OM, ULLRICH A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer (2004) 4:361-370.
16. BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 411:355-365.
17. SALGIA R, SKARIN AT: Molecular abnormalities in lung cancer. J. Clin. Oncol. (1998) 16:1207-1217.
18. DY GK, ADJEI AA: Novel targets for lung cancer therapy: part I. J. Clin. Oncol. (2002) 20:2881-2894.
19. TO CT, TSAO MS: The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol. Rep. (1998) 5:1013-1024.
20. HELDIN CH: Dimerization of cell surface receptors in signal transduction. Cell (1995) 80:213-223.
21. SCHLESSINGER J: Cell signaling by receptor tyrosine kinases. Cell (2000) 103:211-225.
22. LEVI-MONTALCINI R: Effects of mouse tumor transplantation an the nervous system. Ann. NY Acad. Sci. (1952) 55:330-344.
23. COHEN S: The stimulation of epidermal proliferation by a specific protein (EGF). Dev. Biol. (1965) 12:394-407.
24. CARPENTER G, LEMBACH KJ, MORRISON MM, COHEN S: Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J. Biol. Chem. (1975) 250:4297-4304.
25. ULLRICH A, COUSSENS L, HAYFLICK JS et al.: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 309:418-425.
26. YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. (2001) 2:127-137.
27. BLENIS J: Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. USA (1993) 90:5889-5892.
28. BURGERING BM, COFFER PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 376:599-602.
29. MATUOKA K, SHIBASAKI F, SHIBATA M, TAKENAWA T: Ash/Grb-2, a SH2/SH3-containing protein, couples to signaling for mitogenesis and cytoskeletal reorganization by EGF and PDGF. EMBO J. (1993) 12:3467-3473.
30. MARSHALL CJ: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell (1995) 80:179-185.
31. KUO ML, CHUANG SE, LIN MT, YANG SY. The involvement of PI 3-K/ Akt-dependent up-regulation of Mcl-1 in the prevention of apoprosis of Hep3B cells by interleukin-6. Oncogene (2001) 20:677-685.
32. SUHARA T, MANO T, OLIVEIRA BE, WALSH K: Phosphatidylinositot 3-kinase/ Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ. Res. (2001) 89:13-19.
33. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM et al.: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10:105-115.
34. THREADGILL DW, DLUGOSZ AA, HANSEN LA et al.: Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 269:230-234.
35. MIETTINEN PJ, BERGER JE, MENESES J et al.: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature (1995) 376:337-341.
36. SIBILIA M, WAGNER EF: Strain-dependent epithelial defects in mice lacking the EGF receptor. Science (1995) 269:234-238.
37. LUETTEKE NC, QIU TH, FENTON SE et al.: Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development (1999) 126:2739-2750.
38. VELU TJ, BEGUINOT L, VASS WC et al.: Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 238:1408-1410.
39. SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19:183-232.
40. FRANKLIN WA, VEVE R, HIRSCH FR, HELFRICH BA, BUNN PA, JR: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. (2002) 29:3-14.
41. HIRSCH FR, VARELLA-GARCIA M, BUNN PA, JR: et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. (2003) 21:3798-3807.
42. VOLM M, RITTGEN W, DRINGS P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer (1998) 77:663-669.
43. BRABENDER J, DANENBERG KD, METZGER R et al.: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res. (2001) 7:1850-1855.
44. REISSMANN PT, KOGA H, FIGLIN RA, HOLMES EC, SLAMON DJ: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J. Cancer Res. Clin. Oncol. (1999) 125:61-70.
45. PASTORINO U, ANDREOLA S, TAGLIABUE E et al.: Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol. (1997) 15:2858-2865.
46. RUSCH V, KLIMSTRA D, VENKATRAMAN E, PISTERS PW, LANGENFELD J, DMITROVSKY E: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. (1997) 3:515-522.
47. FREDERICK L, WANG XY, ELEY G, JAMES CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. (2000) 60:1383-1387.
48. SCHMIDT MH, FURNARI FB, CAVENEE WK, BOGLER O: Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc. Natl. Acad. Sci. USA (2003) 100:6505-6510.
49. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
50. PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306-13311.
51. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
52. FERRY D, HAMMOND L, RANSON M et al.: Intermittent Oral ZD1839 (Iressa), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), Shows Evidence of Good Tolerability and Activity: Final Results from a Phase I Study. Proc. Am. Soc. Clin. Oncol. (2000) 19:3a Abstract 5E.
53. NEGORO S, NAKAGAWA K, FUKUOKA M et al.: Final Results of a Phase I Intermittent Dose-Escalation Trial of ZD1839 ('Iressa') In Japanese Patients With Various Solid Tumours. Proc. Am. Soc. Clin. Oncol. (2001) 20:324a Abstract 1292.
54. BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. (2002) 20:4292-4302.
55. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 21:2237-2246.
56. GIACCONE G, HERBST RS, MANEGOLD C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 1. J. Clin. Oncol. (2004) 22:777-784.
57. HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J. Clin. Oncol. (2004) 22:785-794.
58. CIARDIELLO F, CAPUTO R, BIANCO R et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053-2063.
59. SIROTNAK FM, ZAKOWSKI MF, MILLER VA, SCHER HI, KRIS MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6:4885-4892.
60. JANNE PA, GURUBHAGAVATULA S, YEAP BY et al.: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa) on an expanded access study. Lung Cancer (2004) 44:221-230.
61. MILLER VA, KRIS MG, SHAH N et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:1103-1109.
62. COHEN MH, WILLIAMS GA, SRIDHARA R et al.: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. (2004) 10:1212-1218.
63. CAPPUZZO F, GREGORC V, ROSSI E et al.: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. (2003) 21:2658-2663.
64. KOSAKA T, YATABE Y, ENDOH H, KUWANO H, TAKAHASHI T, MITSUDOMI T. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer. Biological and Clinical Implications. Cancer. Res. (2004) 64:8919-8923.
65. INOUE A, SAIJO Y, MAEMONDO M et al.: Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 361:137-139.
66. CAMUS P, KUDOH S, EBINA M: Interstitial lung disease associated with drug therapy. Br. J. Cancer (2004) 91(Suppl. 2):S18-S23.
67. TAKANO T, OHE Y, KUSUMOTO M et al.: Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer (2004) 45:93-104.
68. MOYER JD, BARBACCI EG, IWATA KK et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57:4838-4848.
69. POLLACK VA, SAVAGE DM, BAKER DA et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. (1999) 291:739-748.
70. HIGGINS B, KOLINSKY K, SMITH M et al.: Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs (2004) 15:503-512.
71. HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279.
72. YAMAMOTO N, YAMADA Y, SHIMOYAMA T et al.: A Phase I study of erlotinib HCl in Japanese patients with various types of solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:225.
73. PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:3238-3247.
74. KRIS MG, SANDLER A, MILLER V et al.: Cigarette smoking history predicts sensitivity to erlotinib: Results of a Phase II trial in patients with bronchioloalveolar carcinoma (BAC). J. Clin. Oncol. (2004) 22:Abstract 7062.
75. GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22:Abstract 7010.
76. HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE - A Phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22:Abstract 7011.
77. TRAXLER P, BUCHDUNGER E, FURET P et al.: Preclinical profile of PKI166 - a novel and potent EGFR tyrosine kinase inhibitor for clinical development. Proc. Am. Assoc. Cancer Res. (1999) 40:Abstract 100.
78. HOEKSTRA R, DUMEZ H, VAN OOSTEROM AT et al.: A Phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:86a.
79. DUMEZ H, HOEKSTRA R, ESKENS F et al.: A Phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:86a.
80. MURREN JR, PAPADIMITRAKOPOULOU VA, SIZER KC, VAIDYANATHAN S, RAVERA C, ABBRUZZESE JL: A Phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. (2002) 21:95a.
81. RUSNAK DW, LACKEY K, AFFLECK K et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. (2001) 1:85-94.
82. BURRIS HA, TAYLOR C, JONES S et al.: A Phase I study of GW572016 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:248.
83. SPECTOR N, RAEFSKY E, HURWITZ H et al.: Safety, clinical efficacy, and biologic assessments from EGF10004: A randomized Phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc. Am. Soc. Clin. Oncol. (2003) 22:193.
84. MINAMI H, NAKAGAWA K, KAWADA K et al.: A Phase I study of GW572016 in patients with solid tumors. J. Clin. Oncol. (2004) 22:Abstract 3048.
85. VERSOLA M, BURRIS HA, JONES S et al.: Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J. Clin. Oncol. (2004) 22:Abstract.
86. DE BONO JS, SCHWARTZ G, MONROE P et al.: Phase I and pharmacokinetic (PK) study of oral GW572016, a potent reversible dual inhibitor of both erbB1 and erbB2 tyrosine kinase (TK), administered in combination with capecitabine. Proc. Am. Soc. Clin. Oncol. (2003) 22:225.
87. JONES SF, HAINSWORTH JD, SPIGEL DR et al.: A Phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J. Clin. Oncol. (2004) 22:Abstract 2083.
88. WISSNER A, BRAWNER FLOYD MB, RABINDRAN SK et al.: Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg. Med. Chem. Lett. (2002) 12:2893-2897.
89. HIDALGO M, ERLICHMAN C, ROWINSKY EK et al.: Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 65.
90. RINEHART JJ, WILDING G, WILLSON J et al. A Phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 41.
91. NEMUNAITIS JJ, EISEMAN I, CUNNINGHAM C et al.: A Phase I trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:243.
92. CAMPOS SM, SEIDEN MV, OZA A et al.: A Phase II, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. J. Clin. Oncol. (2004) 22:5054.
93. BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J. Clin. Oncol. (2000) 18:904-914.
94. ROBERT F, EZEKIEL MP, SPENCER SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. (2001) 19:3234-3243.
95. ROBERT F, BLUMENSCHEIN G, DICKE K, TSENG J, SALEH MN, NEEDLE M: Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2003) 22:643.
96. KELLY K, HANNA N, ROSENBERG A, BUNN PA, NEEDLE MN: A multi-centered Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:644.
97. GATZEMEIER U, ROSELL R, RAMLAU R et al.: Cetuximab (C225) in combination with cisplatin/vinorelbine versus cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2582.
98. ROSELL R, DANIEL C, RAMLAU R et al.: Randomized Phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) versus CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22:Abstract 7012.
99. KIM ES, MAUER AM, TRAN HT et al.: A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc. Am. Soc. Clin. Oncol. (2003) 22:642.
100. LYNCH TJ, LILENBAUM R, BONOMI P et al.: A Phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22:Abstract 7084.
101. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345.
102. YANG XD, JIA XC, CORVALAN JR, WANG P, DAVIS CG, JAKOBOVITS A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. (1999) 59:1236-1243.
103. YANG XD, JIA XC, CORVALAN JR, WANG P, DAVIS CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. (2001) 38:17-23.
104. YANG XD, WANG P, FREDLIN F, JIA XC, OPPENHEIM JJ, DAVIS CG: Preclinical evaluation of ABX-EGF as a potent anti-tumor agent. Proc. Am. Assoc. Cancer Res. (2002) 43:Abstract 977.
105. FIGLIN RA, BELLDEGRUN AS, CRAWFORD J et al.: ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: Phase I clinical results. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 35.
106. CRAWFORD J, SANDLER AB, HAMMOND LA et al.: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2004) 22:Abstract 7083.
107. BIER H, HOFFMANN T, HAUSER U et al.: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. (2001) 47:519-524.
108. VANHOEFER U, TEWES M, ROJO F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:175-184.
109. KOLLMANNSBERGER C, SCHITTENHELM M, HONECKER F et al.: Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): A phase-I study. Proc. Am. Soc. Clin. Oncol. (2003) 22:627.
110. HOFFMANN T, HAFNER D, BALLO H, HAAS I, BIER H: Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. (1997) 17:4419-4425.
111. MODJTAHEDI H, MOSCATELLO DK, BOX G et al.: Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int. J. Cancer (2003) 105:273-280.
112. MODJTAHEDI H, HICKISH T, NICOLSON M et al.: Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer (1996) 73:228-235.
113. CROMBET-RAMOS T, RAK J, PEREZ R, VILORIA-PETIT A: Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int. J. Cancer (2002) 101:567-575.
114. GILLE J, SWERLICK RA, CAUGHMAN SW: Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J. (1997) 16:750-759.
115. CIARDIELLO F, DAMIANO V, BIANCO R et al.: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. (1996) 88:1770-1776.
116. WINQUIST E, NABID A, SICHERI D et al.: A Phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 926.
117. IZNAGA-ESCOBAR N, RAMIREZ IL, IZQUIERDO JC, SUAREZ L, MORALES D, PEREZ-RODRIGUEZ R: 188Re-labeled anti-epidermal growth factor receptor humanized monoclonal antibody h-R3: labeling conditions, in vitro and in vivo stability. Methods Find. Exp. Clin. Pharmacol. (2003) 25:703-711.
118. RIVA P, SANTIMARIA M, CASI M, ADAMO M, NADA R, INZAGA N: Loco-regional radioimmunotherapy of malignant glioma by means of a humanised antibody hR3 (raised against epidermal growth factor receptors) labelled with Y-90. Proc. Am. Soc. Clin. Oncol. (2003) 22:112.
119. GUYRE PM, GRAZIANO RF, VANCE BA, MORGANELLI PM, FANGER MW: Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J. Immunol. (1989) 143:1650-1655.
120. PFISTER D, ALLA L, ROBER B et al.: A Phase I Trial of the Epidermal Growth Factor Receptor (EGFR)-Directed Bispecific Antibody (BsAB) MDX-447 in Patients with Solid Tumors. Proc. Am. Soc. Clin. Oncol. (1999) 16:Abstract 1667.
121. MATAR P, ROJO F, GUZMAN M, RODRIGUEZ-VILTRO I, ARRIBAS J, BASELGA J: Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, 'Iressa') and a monoclonal antibody (IMC-C225):evidence of synergy. Proc. Am. Assoc. Cancer Res. (2003) 44:800.
122. HUANG S, ARMSTRONG EA, BENAVENTE S, CHINNAIYAN P, HARARI PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. (2004) 64:5355-5362.
123. AKIYAMA T, SUDO C, OGAWARA H, TOYOSHIMA K, YAMAMOTO T.: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science (1986) 232:1644-1646.
124. COUSSENS L, YANG-FENG TL, LIAO YC et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 230:1132-1139.
125. DI FIORE PP, PIERCE JH, KRAUS MH, SEGATTO O, KING CR, AARONSON SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 237:178-182.
126. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
127. TATEISHI M, ISHIDA T, MITSUDOMI T, KANEKO S, SUGIMACHI K: Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer (1991) 27:1372-1375.
128. KERN JA, SLEBOS RJ, TOP B et al.: C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest. (1994) 93:516-520.
129. HAN H, LANDRENEAU RJ, SANTUCCI TS et al.: Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum. Pathol. (2002) 33:105-110.
130. PELLEGRINI C, FALLENI M, MARCHETTI A et al.: HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin. Cancer Res. (2003) 9:3645-3652.
131. MEERT AP, MARTIN B, PAESMANS M et al.: The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br. J. Cancer (2003) 89:959-965.
132. TSAI CM, CHANG KT, PERNG RP et al.: Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst. (1993) 85:897-901.
133. BUNN PA, JR, HELFRICH B, SORIANO AF et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res. (2001) 7:3239-3250.
134. GATZEMEIER U, GROTH G, BUTTS C et al.: Randomized Phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. (2004) 15:19-27.
135. LANGER CJ, STEPHENSON P, THOR A, VANGEL M, JOHNSON DH: Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J. Clin. Oncol. (2004) 22:1180-1187.
136. ZINNER RG, GLISSON BS, FOSSELLA FV et al.: Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a Phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer (2004) 44:99-110.
137. STEPHENS P, HUNTER C, BIGNELL G et al.: Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 431:525-526.
138. LIU Y: The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene (1998) 215:159-169.
139. DUH FM, SCHERER SW, TSUI LC, LERMAN MI, ZBAR B, SCHMIDT L: Gene structure of the human MET protooncogene. Oncogene (1997) 15:1583-1586.
140. MA PC, MAULIK G, CHRISTENSEN J, SALGIA R: c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. (2003) 22:309-325.
141. STOKER M, GHERARDI E, PERRYMAN M, GRAY J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (1987) 327:239-242.
142. NAKAMURA T, NISHIZAWA T, HAGIYA M et al.: Molecular cloning and expression of human hepatocyte growth factor. Nature (1989) 342:440-443.
143. MIYAZAWA K, TSUBOUCHI H, NAKA D et al.: Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. (1989) 163:967-973.
144. ZARNEGAR R, MICHALOPOULOS G: Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. (1989) 49:3314-3320.
145. WEIDNER KM, ARAKAKI N, HARTMANN G et al.: Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl. Acad. Sci. USA (1991) 88:7001-7005.
146. GHERARDI E, STOKER M: Hepatocytes and scatter factor. Nature (1990) 346:228.
147. LOKKER NA, MARK MR, LUIS EA et al.: Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. (1992) 11:2503-2510.
148. SEKI T, HAGIYA M, SHIMONISHI M, NAKAMURA T, SHIMIZU S: Organization of the human hepatocyte growth factor-encoding gene. Gene (1991) 102:213-219.
149. TAMAGNONE L, ARTIGIANI S, CHEN H et al.: Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell (1999) 99:71-80.
150. TAMAGNONE L, COMOGLIO PM: Signalling by semaphorin receptors: cell guidance and beyond. Trends Cell Biol. (2000) 10:377-383.
151. TRUSOLINO L, COMOGLIO PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer (2002) 2:289-300.
152. GRAZIANI A, GRAMAGLIA D, DALLA ZONCA P, COMOGLIO PM: Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J. Biol. Chem. (1993) 268:9165-9168.
153. DI RENZO MF, OLIVERO M, MARTONE T et al.: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene (2000) 19:1547-1555.
154. MAULIK G, KIJIMA T, MA PC et al.: Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. (2002) 8:620-627.
155. PARR C, DAVIES G, NAKAMURA T, MATSUMOTO K, MASON MD, JIANG WG: The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. Biochem. Biophys. Res. Commun. (2001) 285:1330-1337.
156. XIAO GH, JEFFERS M, BELLACOSA A, MITSUUCHI Y, VANDE WOUDE GF, TESTA JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. USA (2001) 98:247-252.
157. DERMAN MP, CUNHA MJ, BARROS EJ, NIGAM SK, CANTLEY LG: HGF-mediated chemotaxis and tubulogenesis require activation of the phosphatidylinositol 3-kinase. Am. J. Physiol. (1995)
158. POTEMPA S, RIDLEY AJ: Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell (1998) 9:2185-2200.
159. SACHS M, BROHMANN H, ZECHNER D et al.: Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. (2000) 150:1375-1384.
160. PONZETTO C, BARDELLI A, ZHEN Z et al.: A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 77:261-271.
161. GU H, NEEL BG: The 'Gab' in signal transduction. Trends Cell Biol. (2003) 13:122-130.
162. RIDLEY AJ, COMOGLIO PM, HALL A: Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol. Cell. Biol. (1995) 15:1110-1122.
163. PETRELLI A, GILESTRO GF, LANZARDO S, COMOGLIO PM, MIGONE N, GIORDANO S: The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 416:187-190.
164. COOPER CS, PARK M, BLAIR DG et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 311:29-33.
165. PARK M, DEAN M, COOPER CS et al.: Mechanism of met oncogene activation. Cell (1986) 45:895-904.
166. DI RENZO MF, NARSIMHAN RP, OLIVERO M et al.: Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene (1991) 6:1997-2003.
167. WANG R, FERRELL LD, FAOUZI S, MAHER JJ, BISHOP JM: Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. (2001) 153:1023-1034.
168. PESCHARD P, FOURNIER TM, LAMORTE L et al.: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell. (2001) 8:995-1004.
169. SCHMIDT L, DUH FM, CHEN F et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. (1997) 16:68-73.
170. FERRACINI R, DI RENZO MF, SCOTLANDI K et al.: The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 10:739-749.
171. FERRACINI R, OLIVERO M, DI RENZO ME et al.: Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene (1996) 12:1697-1705.
172. TUCK AB, PARK M, STERNS EE, BOAG A, ELLIOTT BE: Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am. J. Pathol. (1996) 148:225-232.
173. DI RENZO MF, OLIVERO M, FERRO S et al.: Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 7:2549-2553.
174. DI RENZO MF, OLIVERO M, KATSAROS D et al.: Overexpression of the Met/HGF receptor in ovarian cancer. Int. J. Cancer (1994) 58:658-662.
175. DI RENZO MF, POULSOM R, OLIVERO M, COMOGLIO PM, LEMOINE NR: Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. (1995) 55:1129-1138.
176. HUMPHREY PA, ZHU X, ZARNEGAR R et al.: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. (1995) 147:386-396.
177. UEKI T, FUJIMOTO J, SUZUKI T, YAMAMOTO H, OKAMOTO E: Expression of hepacocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology (1997) 25:619-623.
178. WIELENGA VJ, VAN DER VOORT R, TAHER TE et al.: Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am. J. Pathol. (2000) 157:1563-1573.
179. RYGAARD K, NAKAMURA T, SPANG-THOMSEN M: Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br. J. Cancer (1993) 67:37-46.
180. ICHIMURA E, MAESHIMA A, NAKAJIMA T, NAKAMURA T: Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn. J. Cancer Res. (1996) 87:1063-1069.
181. MA PC, JAGADEESWARAN R, JAGADEESH S et al.: Functional Expression And Mutations of c-Met And Its Therapeutic Inhibition With Su11274 And Sirna In Non-Small Cell Lung Cancer. Cancer Res. (2005) 65:1-10.
182. MA PC, KIJIMA T, MAULIK G et al.: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. (2003) 63:6272-6281.
183. LEE JH, HAN SU, CHO H et al.: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 19:4947-4953.
184. SIEGFRIED JM, WEISSFELD LA, LUKETICH JD, WEYANT RJ, GUBISH CT, LANDRENEAU RJ: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann. Thorac. Surg. (1998) 66:1915-1918.
185. BHARTI A, MA PC, MAULIK G et al.: Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. (2004) 24:1031-1038.
186. OTSUKA T, JAKUBCZAK J, VIEIRA W et al.: Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol. Cell. Biol. (2000) 20:2055-2065.
187. DATE K, MATSUMOTO K, SHIMURA H, TANAKA M, NAKAMURA T: HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett. (1997) 420:1-6.
188. TOMIOKA D, MAEHARA N, KUBA K et al.: Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. (2001) 61:7518-7524.
189. MARTIN TA, PARR C, DAVIES G et al.: Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis (2003) 24:1317-1323.
190. BROCKMANN MA, PAPADIMITRIOU A, BRANDT M, FILLBRANDT R, WESTPHAL M, LAMSZUS K: Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res. (2003) 9:4578-4585.
191. KUBA K, MATSUMOTO K, DATE K, SHIMURA H, TANAKA M, NAKAMURA T: HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. (2000) 60:6737-6743.
192. PARR C, HISCOX S, NAKAMURA T, MATSUMOTO K, JIANG WG: Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int. J. Cancer (2000) 85:563-570.
193. MARK MR, LOKKER NA, ZIONCHECK TF, LUIS EA, GODOWSKI PJ: Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding. J. Biol. Chem. (1992) 267:26166-26171.
194. MICHIELI P, BASILICO C, PENNACCHIETTI S et al.: Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene (1999) 18:5221-5231.
195. WEBB CP, HOSE CD, KOOCHEKPOUR S et al.: The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. (2000) 60:342-349.
196. MACHIDA H, MATSUMOTO Y, SHIRAI M, KUBOTA N: Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int. J. Radiat. Biol. (2003) 79:973-980.
197. RUSSELL JS, BURGAN W, OSWALD KA, CAMPHAUSEN K, TOFILON PJ: Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin. Cancer Res. (2003) 9:3749-3755.
198. SATTLER M, PRIDE YB, MA P et al.: A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. (2003) 63:5462-5469.
199. DANILKOVITCH-MIAGKOVA A, ZBAR B: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. (2002) 109:863-867.
200. BERTHOU S, AEBERSOLD DM, SCHMIDT LS et al.: The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene (2004) 23:5387-5393.
201. WANG X, LE P, LIANG C et al.: Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol. Cancer Ther. (2003) 2:1085-1092.
202. CHRISTENSEN JG, SCHRECK R, BURROWS J et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. (2003) 63:7345-7355.
203. KONG-BELTRAN M, STAMOS J, WICKRAMASINGHE D: The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell (2004) 6:75-84.
204. STABILE LP, LYKER JS, HUANG L, SIEGFRIED JM: Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther (2004) 11:325-335.
205. ABOUNADER R, LAL B, LUDDY C et al.: In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. (2002) 16:108-110.
206. MA PC, JAGADEESWARAN R, JAGADEESH S et al.: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and siRNA in non-small cell lung cancer. Cancer Res. (2004) Accepted.
207. ALGIRE GH, CHALKLEY HW, LEGALLAIS FY, PARK HD: Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J. Natl. Cancer Inst. (1945) 6:73-85.
208. LEUNG DW, CACHIANES G, KUANG WJ, GOEDDEL DV, FERRARA N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246:1306-1309.
209. SENGER DR, CONNOLLY DT, VAN DE WATER L, FEDER J, DVORAK HF: Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. (1990) 50:1774-1778.
210. OLOFSSON B, PAJUSOLA K, KAIPAINEN A et al.: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA (1996) 93:2576-2581.
211. JOUKOV V, PAJUSOLA K, KAIPAINEN A et al.: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. (1996) 15:1751.
212. LEE J, GRAY A, YUAN J, LUOH SM, AVRAHAM H, WOOD WI: Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA (1996) 93:1988-1992.
213. ORLANDINI M, MARCONCINI L, FERRUZZI R, OLIVIERO S: Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. USA (1996) 93:11675-11680.
214. PARK JE, CHEN HH, WINER J, HOUCK KA, FERRARA N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 bur not to Flk-1/KDR. J. Biol. Chem. (1994) 269:25646-25654.
215. DE VRIES C, ESCOBEDO JA, UENO H, HOUCK K, FERRARA N, WILLIAMS LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 255:989-991.
216. TERMAN BI, DOUGHER-VERMAZEN M, CARRION ME et al.: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. (1992) 187:1579-1586.
217. GALLAND F, KARAMYSHEVA A, PEBUSQUE MJ et al.: The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene (1993) 8:1233-1240.
218. SOKER S, TAKASHIMA S, MIAO HQ, NEUFELD G, KLAGSBRUN M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 92:735-745.
219. SHIBUYA M, YAMAGUCHI S, YAMANE A et al.: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene (1990) 5:519-524.
220. KAIPAINEN A, KORHONEN J, MUSTONEN T et al.: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA (1995) 92:3566-3570.
221. DOR Y, PORAT R, KESHET E: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol. (2001) 280:C1367-74.
222. MOLE DR, MAXWELL PH, PUGH CW, RATCLIFFE PJ: Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life (2001) 52:43-47.
223. GOLDMAN CK, KIM J, WONG WL, KING V, BROCK T, GILLESPIE GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell (1993) 4:121-133.
224. MARU Y, YAMAGUCHI S, SHIBUYA M: Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene (1998) 16:2585-2595.
225. GERBER HP, HILLAN KJ, RYAN AM et al.: VEGF is required for growth and survival in neonatal mice. Development (1999) 126:1149-1159.
226. KITAMOTO Y, TOKUNAGA H, TOMITA K: Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J. Clin. Invest. (1997) 99:2351-2357.
227. RYAN AM, EPPLER DB, HAGLER KE et al.: Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol. (1999) 27:78-86.
228. CARMELIET P, FERREIRA V, BREIER G et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380:435-439.
229. FERRARA N, CHEN H, DAVIS-SMYTH T et al.: Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. (1998) 4:336-340.
230. GERBER HP, MCMURTREY A, KOWALSKI J et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1 /KDR activation. J. Biol. Chem. (1998) 273:30336-30343.
231. TAKAHASHI T, UENO H, SHIBUYA M: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene (1999) 18:2221-2230.
232. KANNO S, ODA N, ABE M et al.: Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene (2000) 19:2138-2146.
233. O'BYRNE KJ, KOUKOURAKIS MI, GIATROMANOLAKI A et al.: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br. J. Cancer (2000) 82:1427-1432.
234. MARROGI AJ, TRAVIS WD, WELSH JA et al.: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin. Cancer Res. (2000) 6:4739-4744.
235. BROWN LF, BERSE B, JACKMAN RW et al.: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. (1993) 143:1255-1262.
236. BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. (1995) 26:86-91.
237. TOI M, KONDO S, SUZUKI H et al.: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer (1996) 77:1101-1106.
238. TAKAHASHI Y, KITADAI Y, BUCANA CD, CLEARY KR, ELLIS LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55:3964-3968.
239. SUZUKI K, HAYASHI N, MIYAMOTO Y et al.: Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. (1996) 56:3004-3009.
240. ABU-JAWDEH GM, FAIX JD, NILOFF J et al.: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. (1996) 74:1105-1115.
241. MATTERN J, KOOMAGI R, VOLM M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer (1996) 73:931-934.
242. OHTA Y, ENDO Y, TANAKA M et al.: Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin. Cancer Res. (1996) 2:1411-1416.
243. VOLM M, KOOMAGI R, KAUFMANN M, MATTERN J, STAMMLER G: Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas. Clin. Exp. Metastasis (1996) 14:209-214.
244. VOLM M, KOOMAGI R, MATTERN J: Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. (1996) 16:213-217.
245. HARPOLE DH, JR:, Richards WG, Herndon JE, 2nd, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann. Thorac. Surg. (1996) 61:1470-1476.
246. BAILLIE R, CARLILE J, PENDLETON N, SCHOR AM: Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J. Clin. Pathol. (2001) 54:116-120.
247. HAN H, SILVERMAN JF, SANTUCCI TS et al.: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann. Surg. Oncol. (2001) 8:72-79.
248. YUAN A, YU CJ, KUO SH et al.: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. (2001) 19:432-441.
249. OHTA Y, NOZAKI Z, NOZAWA H et al.: The predictive value of vascular endothetial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer. Jpn. J. Cancer Res. (2001) 92:361-366.
250. DECAUSSIN M, SARTELET H, ROBERT C et al.: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J. Pathol. (1999) 188:369-377.
251. MEERT AP, PAESMANS M, MARTIN B et al.: The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer (2002) 87:694-701.
252. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593-4599.
253. JAIN RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. (2001) 7:987-989.
254. GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19:843-850.
255. HERBST RS, TAKEUCHI H, TEICHER BA: Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol. (1998) 41:497-504.
256. MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. (2001) 19:851-856.
257. JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:2184-2191.
258. GRAY R, GIANTONIO BJ, O'DWYER PJ, SANDLER A, MILLER K, COMIS RL: The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). Proc. Am. Soc. Clin. Oncol. (2003) 22:206.
259. ASANO M, YUKITA A, SUZUKI H: Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn. J. Cancer Res. (1999) 90:93-100.
260. JAYSON GC, ZWEIT J, JACKSON A et al.: Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst. (2002) 94:1484-1493.
261. WITTE L, HICKLIN DJ, ZHU Z et al.: Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. (1998) 17:155-161.
262. DAVIS DW, INOUE K, DINNEY CP, HICKLIN DJ, ABBRUZZESE JL, MCCONKEY DJ: Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res. (2004) 64:4601-4610.
263. SWEENEY P, KARASHIMA T, KIM SJ et al.: And-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase Type 9 production. Clin. Cancer Res. (2002) 8:2714-2724.
264. BRUNS CJ, SHRADER M, HARBISON MT et al.: Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int. J. Cancer (2002) 102:101-108.
265. KOZIN SV, BOUCHER Y, HICKLIN DJ, BOHLEN P, JAIN RK, SUIT HD: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. (2001) 61:39-44.
266. FENTON BM, PAONI SF, DING I: Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res. (2004) 64:5712-5719.
267. HENNEQUIN LF, STOKES ES, THOMAS AP et al.: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. (2002) 45:1300-1312.
268. WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62:4645-4655.
269. HURWITZ H, HOLDEN SN, ECKHARDT SG et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 325.
270. HEYMACH JV, DONG RP, DIMERY I et al.: ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized Phase II study. J. Clin. Oncol. (2004) 22:Abstract 3051.
271. FONG TA, SHAWVER LK, SUN L et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99-106.
272. LARA PN, JR:, Quinn DI, Margolin K et al. SU5416 plus interferon alpha in advanced renal cell carcinoma: a Phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin. Cancer Res. (2003) 9:4772-4781.
273. PETERSON AC, SWIGER S, STADLER W, KARCZMAR G, GAJEWSKI T: Phase II study of the Flk-1 TK inhibitor SU5416 in patients with advanced melanoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:712.
274. ZAHALSKY AJ, WONG RJ, LIS E et al.: Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 902.
275. O'FARRELL AM, YUEN HA, SMOLICH B et al.: Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk. Res. (2004) 28:679-689.
276. ZANGARI M, ANAISSIE E, STOPECK A et al.: Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. (2004) 10:88-95.
277. AKLILU M, KINDLER HL, GAJEWSKI TF, VOGELZANG NJ, VOKES EE, STADLER WM: Toxicities of the antiangiogenic agent SU5416 in Phase II studies. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 1921.
278. KUENEN BC, ROSEN L, SMIT EF et al.: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. (2002) 20:1657-1667.
279. BOLD G, ALTMANN KH, FREI J et al.: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. (2000) 43:2310-2323.
280. STEWARD WP, THOMAS A, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:Abstract 3556.
281. SCHLEUCHER N, TRARBACH T, JUNKER U et al.: Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. J Clin. Oncol. (2004) 22:Abstract 3558.
282. GEORGE D, MICHAELSON D, OH WK et al.: Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:385.
283. REARDON D, FRIEDMAN H, YUNG WKA et al.: A Phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. (2004) 22.
284. WICKMAN G, HALLIN M, DILLON R et al.: Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG0 13736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc. Am. Assoc. Cancer Res. (2003) 44:A3780.
285. PETIT AM, RAK J, HUNG MC et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. (1997) 151:1523-1530.
286. TRAXLER P, ALLEGRINI PR, BRANDT R et al.: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. (2004) 64:4931-4941.
287. BEEBE JS, JANI JP, KNAUTH E et al.: Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. (2003) 63:7301-7309.
288. SUN J, BLASKOVICH MA, JAIN RK et al.: Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res. (2004) 64:3586-3592.
289. HOLASH J, DAVIS S, PAPADOPOULOS N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA (2002) 99:11393-8.
290. HUANG J, FRISCHER JS, SERUR A et al.: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. USA (2003) 100:7785-7790.
291. DUPONT J, SCHWARTZ L, KOUTCHER J et al.: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. J. Clin. Oncol. (2004) 22:Abstract 3009.
292. BESMER P, MURPHY JE, GEORGE PC et al.: A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature (1986) 320:415-421.
293. D'AURIOL L, MATTEI MG, ANDRE C, GALIBERT F: Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum. Genet. (1988) 78:374-376.
294. ZSEBO KM, WILLIAMS DA, GEISSLER EN et al.: Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell (1990) 63:213-224.
295. ZSEBO KM, WYPYCH J, MCNIECE IK et al.: Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell (1990) 63:195-201.
296. MARTIN FH, SUGGS SV, LANGLEY KE et al.: Primary structure and functional expression of rat and human stem cell factor DNAs. Cell (1990) 63:203-211.
297. LEMMON MA, PINCHASI D, ZHOU M, LAX I, SCHLESSINGER J: Kit receptor dimerization is driven by bivalent binding of stem cell factor. J. Biol. Chem. (1997) 272:6311-6317.
298. BLECHMAN JM, LEV S, BARG J et al.: The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell (1995) 80:103-113.
299. LUX ML, RUBIN BF, BIASE TL et al.: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. (2000) 156:791-795.
300. NAGATA H, WOROBEC AS, OH CK et al.: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA (1995) 92:10560-10564.
301. HIDA T, UEDA R, SEKIDO Y et al.: Ectopic expression of c-kit in small-cell lung cancer. Int. J. Cancer Suppl. (1994) 8:108-109.
302. SEKIDO Y, OBATA Y, UEDA R et al.: Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. (1991) 51:2416-2419.
303. MICKE P, BASRAI M, FALDUM A et al.: Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. (2003) 9:188-194.
304. NAFEM M, DAHIYA M, CLARK JI, CREECH SD, ALKAN S: Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum. Pathol. (2002) 33:1182-1187.
305. POTTI A, MOAZZAM N, RAMAR K, HANEKOM DS, KARGAS S, KOCH M: CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann. Oncol. (2003) 14:894-897.
306. JOHNSON BE, FISCHER T, FISCHER B et al.: Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. (2003) 9:5880-5887.
307. ROSSI G, CAVAZZA A, MARCHIONI A et al.: Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod. Pathol. (2003) 16:1041-1047.
308. JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. (2001) 344:1052-1056.
309. KRYSTAL GW, HONSAWEK S, LITZ J, BUCHDUNGER E: The selective tyrosine kinase inhibitor ST1571 inhibits small cell lung cancer growth. Clin. Cancer Res. (2000) 6:3319-3326.
310. WANG WL, HEALY ME, SATTLER M et al.: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene (2000) 19:3521-3528.
311. MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327-337.
312. ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2:471-478.